http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Longeveron+Inc.++++++++++++++++++++++++Filed+by%3A+Logos+Global+Management+LP/27048440.html si-local-file:///var/storage/secattach/20260910/27048440.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Longeveron+Inc.++++++++++++++++++++++++Filed+by%3A+Logos+Global+Management+LP/27048440.html Thu, 10 Sep 2026 16:07:00 -0400 LGVN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17/26975992.html si-local-file:///var/storage/secattach/20260825/26975992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17/26975992.html Tue, 25 Aug 2026 19:03:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17/26975992.html si-local-file:///var/storage/secattach/20260825/26975992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17/26975992.html Tue, 25 Aug 2026 19:03:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975906.html si-local-file:///var/storage/secattach/20260825/26975906.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975906.html Tue, 25 Aug 2026 18:05:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975906.html si-local-file:///var/storage/secattach/20260825/26975906.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975906.html Tue, 25 Aug 2026 18:05:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975895.html si-local-file:///var/storage/secattach/20260825/26975895.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975895.html Tue, 25 Aug 2026 18:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975895.html si-local-file:///var/storage/secattach/20260825/26975895.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+17++Filed+by%3A+Jhaveri+Nirav+S./26975895.html Tue, 25 Aug 2026 18:00:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+20/26968279.html si-local-file:///var/storage/secattach/20260824/26968279.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+20/26968279.html Mon, 24 Aug 2026 16:15:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+20/26968279.html si-local-file:///var/storage/secattach/20260824/26968279.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+20/26968279.html Mon, 24 Aug 2026 16:15:00 -0400 LGVN O.49866458 http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html <p>Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.</p> <p>The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html Mon, 24 Aug 2026 16:05:17 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html <p>Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.</p> <p>The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html Mon, 24 Aug 2026 16:05:17 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html <p>Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.</p> <p>The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html Mon, 24 Aug 2026 16:05:17 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html <p>Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.</p> <p>The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html Mon, 24 Aug 2026 16:05:17 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html <p>Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.</p> <p>The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the http://www.streetinsider.com/Stock+Splits/Longeveron+sets+1-for-10+reverse+stock+split+effective+Aug.+26/26968078.html Mon, 24 Aug 2026 16:05:17 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Press+Releases/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html <p align="justify">MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbfeR88OKABcWbOd0ZyuETNF-4E2zgEWunJZaeYyqicGxyUBqpjiGZ8ckwjE3BJSAews-YzS2T_zz_iAHmCz0zvMDXBwXmR2Pj3ceakjzOA=" rel="nofollow" target="_blank">Longeveron Inc.</a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+1-for-10+Reverse+Stock+Split/26968064.html Mon, 24 Aug 2026 16:05:00 -0400 A.23164265 LGVN LGVNR O.01114765 O.49866458 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+19++Filed+by%3A+Ascheim+Deborah/26962633.html si-local-file:///var/storage/secattach/20260821/26962633.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Longeveron+Inc.+++++++++++For%3A+Aug+19++Filed+by%3A+Ascheim+Deborah/26962633.html Fri, 21 Aug 2026 18:00:00 -0400 LGVN O.49866458